A Year in Review: Experts Illuminate the Potential of ADCs Targeting HER2, HER3, and TROP-2 in NSCLC

Learn how experts are integrating the latest data on ADCs into clinical care of NSCLC with downloadable slides and an archived webcast of a live webinar, along with a focused commentary.

Share

Program Content

Activities

ADCs for NSCLC
My Take on Recent Developments in Antibody‒Drug Conjugates for NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 30, 2023

Activities

HER2 ADCs in NSCLC
A Year in Review: ADCs Targeting HER2 in NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 29, 2024

TROP-2 ADCs in NSCLC
A Year in Review: ADCs Targeting TROP-2 in NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 29, 2024

HER3 ADCs in NSCLC
A Year in Review: ADCs Targeting HER3 in NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 29, 2024

Activities

Targeted ADCs in NSCLC
Optimizing NSCLC Treatment: Potential of ADCs Targeting HER2, HER3, and TROP-2
Video
Congratulations: You achieved a completion on 04/09/2022

Released: February 05, 2024

Expires: February 04, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.